QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Dutch diagnostics firm MRC Holland said Thursday that its liquid biopsy test for Peutz-Jeghers syndrome has been certified under Europe's In Vitro Diagnostic Regulation (IVDR).

In vitro fertilization embryos are prone to chromosomal aneuploidy abnormalities. Chromosome aneuploidy refers to the increase or decrease in the number of a single chromosome or multiple chromosomes.

Illumina and Macrogen announced on Monday that they are collaborating to sequence and analyze 145,952 genomes as part of South Korea's National Bio Big Data project.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company’s ongoing prospective development and validation study, Castle’s pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater reduction in Eczema Area and Severity Index (EASI) score (EASI90) at three months. Assuming successful validation, the Company currently expects to launch its pipeline test by the end of 2025.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera’s Empower hereditary cancer test the opportunity for further risk assessment using MyOme’s integrated polygenic risk score.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as part of the updated “Advanced Tools” table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) .

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024.

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announces today that it has expanded its strategic Alliance Agreement with QIAGEN N.V. (HQ: Venlo, The Netherlands; CEO: Thierry Bernard) to deepen their collaboration in genetic testing, including research and development, production, clinical development, and sales-marketing.

On 30 July, Information Office of Shanghai Municipality held a press briefing, introducing the details of the “Several Opinions on Supporting the Innovation and Development of the Entire Biomedicine Industry Chain.”